Dashboard
1
Poor Management Efficiency with a low ROCE of 11.13%
- The company has been able to generate a Return on Capital Employed (avg) of 11.13% signifying low profitability per unit of total capital (equity and debt)
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 19.70
3
Poor long term growth as Net Sales has grown by an annual rate of 1.85% and Operating profit at 7.70% over the last 5 years
4
Flat results in Jun 25
5
With ROE of 10.62%, it has a Attractive valuation with a 1.49 Price to Book Value
6
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
EUR 105,746 Million ()
14.00
NA
4.57%
0.08
10.62%
1.51
Revenue and Profits:
Net Sales:
8,810 Million
(Quarterly Results - Mar 2015)
Net Profit:
1,055 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.25%
0%
3.25%
6 Months
-4.97%
0%
-4.97%
1 Year
-8.13%
0%
-8.13%
2 Years
-5.18%
0%
-5.18%
3 Years
-5.87%
0%
-5.87%
4 Years
-3.71%
0%
-3.71%
5 Years
6.69%
0%
6.69%
Sanofi for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
1.85%
EBIT Growth (5y)
7.70%
EBIT to Interest (avg)
19.70
Debt to EBITDA (avg)
0.68
Net Debt to Equity (avg)
0.11
Sales to Capital Employed (avg)
0.45
Tax Ratio
17.98%
Dividend Payout Ratio
88.23%
Pledged Shares
0
Institutional Holding
0.07%
ROCE (avg)
11.13%
ROE (avg)
12.55%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
1.49
EV to EBIT
11.09
EV to EBITDA
7.92
EV to Capital Employed
1.46
EV to Sales
2.76
PEG Ratio
0.80
Dividend Yield
4.63%
ROCE (Latest)
13.12%
ROE (Latest)
10.62%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
Bearish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot : Dec 2023
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 6 Foreign Institutions (0.03%)
Strategic Entities with highest holding
Highest Public shareholder
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
41,081.00
37,817.00
8.63%
Operating Profit (PBDIT) excl Other Income
13,136.00
12,267.00
7.08%
Interest
596.00
522.00
14.18%
Exceptional Items
-1,810.00
-2,099.00
13.77%
Consolidate Net Profit
5,554.00
5,098.00
8.94%
Operating Profit Margin (Excl OI)
231.40%
205.90%
2.55%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 8.63% vs -12.05% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 8.94% vs -39.91% in Dec 2023
About Sanofi 
Sanofi
Pharmaceuticals & Biotechnology
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.
Company Coordinates 
Company Details
54 rue la Boetie , PARIS None : 75008
Registrar Details






